comparemela.com

Latest Breaking News On - Crick avenue - Page 2 : comparemela.com

AstraZeneca : Voydeya approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular haemolysis in adults with the rare disease PNH - Form 6-K -April 02, 2024 at 08:48 am EDT

a9026i FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

University of washington medical centerUnited statesUnited kingdomGlasgow cityMarc dunoyerAdrian kempBart scottDivision of hematologyEuropean hematology associationSecurities exchangeCompany secretaryEuropean medicines agencyInvestor relations teamCommission file numberAlexion pharmaceuticals incEuropean union

AstraZeneca : Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer - Form 6-K -April 02, 2024 at 07:58 am EDT

a9023i FORM 6-K SECURITIES AND EXCHANGE COMMISSION .

United kingdomUnited statesSan antonioDaiichi sankyo biologicsAdrian kempSusan galbraithDaiichi sankyoKen takeshitaNational cancer instituteCompany secretaryDrug administrationCommission file numberSecurities exchangeEuropean society for medical oncology congressWorld health organizationMerck co inc

AstraZeneca : Transparency Directive - Form 6-K -April 02, 2024 at 01:26 pm EDT

a9592i FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United kingdomUnited statesAdrian kempSecurities exchangeCompany secretaryInvestor relations teamCommission file numberUnited kingdom financial conduct authority disclosureForeign issuerSecurities exchange actFile numberCrick avenueRegulationst ruleUnited kingdom financial conduct authorityTransparency ruleRare diseases

AstraZeneca : Ultomiris approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) - Form 6-K -March 25, 2024 at 07:31 am EDT

a0626i FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or.

United statesUnited kingdomNew zealandMarc dunoyerSeanj pittockAdrian kempNeuromyelitis opticaHistochem cytochemDrug administrationMayo neuroimmunology laboratoryMayo clinic centerSecurities exchangeEuropean unionInvestor relations teamAlexion pharmaceuticals incCommission file number

AstraZeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K -March 12, 2024 at 07:32 am EDT

astrazenecaplc-5242g FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to.

United kingdomUnited statesPascal soriotAdrian kempCommission file numberSecurities exchangeCompany secretaryInvestor relations teamEuropean union withdrawalForeign issuerSecurities exchange actFile numberCrick avenueRegulationst rulePerson discharging managerial responsibilitiesOrdinary shares

vimarsana © 2020. All Rights Reserved.